Table 1.

Demographics of patients randomized to MP alone or LDMTX plus MP or HDMTX plus MP

DemographicMP alone
(n = 76)
LDMTX plus MP
(n = 83)
HDMTX plus MP
(n = 74)
Intergroup
comparison, P
Age, y (range) 5.9 5.9 5.9 .74 
 (0.1-18.6) (0.5-17.1) (0.3-18.8)  
WBC day 0, × 109/L (range) 6.3 7.5 7.4 .83 
 (1-225) (1-399) (1-276)  
Sex     
 Male 42 52 40 .49 
 Female 34 31 34  
Immunophenotype     
 T lineage 14 13 11  
 B lineage 61 70 62 .82 
  Nonhyperdiploid 38 44 43  
  Hyperdiploid 23 26 19  
 Unknown  
No. of patients with uricolytics administered within 72 h prior to
bone marrow diagnosis 
    
 Urate oxidase .22  
 Allopurinol alone or with urate oxidase  
 None 67 80 67  
No. of patients with uricolytics administered within 72 h of posttreatment bone marrow sample     
 Urate oxidase 45 52 37 .44  
 Allopurinol alone or with urate oxidase  
 None 26 26 28  
DemographicMP alone
(n = 76)
LDMTX plus MP
(n = 83)
HDMTX plus MP
(n = 74)
Intergroup
comparison, P
Age, y (range) 5.9 5.9 5.9 .74 
 (0.1-18.6) (0.5-17.1) (0.3-18.8)  
WBC day 0, × 109/L (range) 6.3 7.5 7.4 .83 
 (1-225) (1-399) (1-276)  
Sex     
 Male 42 52 40 .49 
 Female 34 31 34  
Immunophenotype     
 T lineage 14 13 11  
 B lineage 61 70 62 .82 
  Nonhyperdiploid 38 44 43  
  Hyperdiploid 23 26 19  
 Unknown  
No. of patients with uricolytics administered within 72 h prior to
bone marrow diagnosis 
    
 Urate oxidase .22  
 Allopurinol alone or with urate oxidase  
 None 67 80 67  
No. of patients with uricolytics administered within 72 h of posttreatment bone marrow sample     
 Urate oxidase 45 52 37 .44  
 Allopurinol alone or with urate oxidase  
 None 26 26 28  

All results are median (range) for quantitative variables.

WBC indicates white blood count.

or Create an Account

Close Modal
Close Modal